2nd Translational Digital Pathology and AI Summit on September 09-11, 2025 in Boston, United States

Achieve Diagnostic Accuracy for Patients Through Translational Digital Pathology

Digital pathology is transforming the industry. Its extraordinary impact now spans modalities, therapeutic areas, and applications, making it nearly impossible to capture its full scope. With momentum continuing to build, breakthroughs like Roche and AstraZeneca’s first AI-driven CDx approval are pushing the field into an exciting new era.

Yet, to fully unlock the potential of this revolutionary technology, critical challenges must be addressed. From implementation and standardization to reimbursement and adoption, the field must come together to ask the right questions, and find the best answers, that will ensure digital pathology delivers on its promise: improving patient stratification, enabling real-time data insights, and helping bring the right therapies to the right patients with maximum impact.

Join the 2nd Translational Digital Pathology and AI Summit to stay at the forefront of innovation as pioneers in this space unite once again to share their latest data, novel strategies, and industry-changing insights designed to help you advance your pathology workflows in the digital era.

URLs:

Tickets: https://go.evvnt.com/3139657-0?pid=10008

Brochure: https://go.evvnt.com/3139657-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Conference + 2 Workshops - Drug Developer Pricing: USD 4197.00,

Conference + 1 Workshop - Drug Developer Pricing: USD 3598.00,

Conference Only - Drug Developer Pricing: USD 2999.00,

Conference + 2 Workshops - Solution Provider Pricing: USD 5097.00,

Conference + 1 Workshop - Solution Provider Pricing: USD 4398.00,

Conference Only - Solution Provider Pricing: USD 3699.00,

Conference + 2 Workshops - Academic Pricing: USD 3597.00,

Conference + 1 Workshop - Academic Pricing: USD 3098.00,

Conference Only - Academic Pricing: USD 2599.00

Speakers: Curtis Colleton, Principal Executive Director - Pathology Research Fellow, Vertex Pharmaceuticals, David Soong, Director - Translational Data Science, Genmab, Dinesh Bangari, Head of Global Discovery Pathology and Multimodal Imaging - Translational Models Research Platform, Sanofi, Frank Policht, Director - Diagnostics and Biomarker Development, Genmab, Javier Perez, Senior Director - Precision Medicine Dx and Digital Pathology (DP/AI) Strategy - Oncology, Regeneron Pharmaceuticals, Jennifer Quigley, Senior Director and Head Precision Health and Partnerships, BioNTech RNA Pharmaceuticals, Jimena Trillo Tinoco, Director - Translational Pathology, Daiichi Sankyo, Joseph Maxwell, Director- Early Clinical Development, Translational Biomarker , GI-TAU Lead, Takeda Pharmaceutical, Kristine Garside, Director - Digital Health and Global Commercial Strategy Organization, Johnson and Johnson, Lucy Phillips, Senior Principal Pathologist, Abbvie, Mark Gustavson, Senior Director and Head of Computational Pathology Strategic Partnerships, AstraZeneca, Michail Shipitsin, Vice President - Biomarker Research and Development, Acrivon Therapeutics, Qing Li, Director - Pathology, Clinical Development, Oncology, Moderna, Ralph Riley, Director - Precision Medicine Access and Policy Strategy, Johnson and Johnson, Robin Edwards, Vice President - Translational Medicine, MacroGenics, Stefan Kirov, Head of Computational Biology, Flare Therapeutics, Tom Richardson, Companion Diagnostics Pathologist, Merck and Co, Vandana Gupta, Scientific Director, Takeda Pharmaceutical, Xavier Palazzi, Vice President and Head of Global Pathology, AstraZeneca